WALDENSTROM MACROGLOBULINEMIA

This study is testing a combination of three drugs for people newly diagnosed with Waldenstrom's macroglobulinemia, a rare type of blood cancer. Participants receive standard chemotherapy (bendamustine and rituximab) for six months, plus a newer pill called acalabrutinib for one …

This early-stage study is testing the safety and initial effectiveness of a new oral drug called LOXO-338 for patients with advanced blood cancers like leukemia and lymphoma who have already received standard therapies. The trial has two parts: first testing LOXO-338 alone, and t…

This study is testing a new combination of three drugs (bortezomib, rituximab, and ibrutinib) for people newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this 'chemotherapy-free' approach can effectively control the disease while po…

This study is testing a new drug called sonrotoclax, both by itself and combined with another drug called zanubrutinib, for people with Waldenström Macroglobulinemia, a rare blood cancer. It aims to see if these treatments can shrink the cancer and control the disease, while also…

This study is testing an experimental drug called iopofosine I 131 in people with various advanced B-cell blood cancers that have come back or stopped responding to standard treatments. The drug is designed to deliver radiation directly to cancer cells. The main goal is to see if…

This study is testing whether combining the drug acalabrutinib with an antibody treatment (like rituximab) is safe and effective for people with nerve damage (neuropathy) caused by specific blood conditions. The goal is to control the underlying disease and improve or stabilize n…

This early-stage study is testing a new combination of three drugs for people whose non-Hodgkin's lymphoma has come back after prior treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and …

This study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…

This study is testing a two-drug combination for people with certain slow-growing types of B-cell lymphoma who have not yet received treatment. The goal is to see how well the pill ixazomib works when given with the antibody drug rituximab to shrink tumors and control the cancer.…

This study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…

This study aims to understand why some families have a higher risk of developing blood and lymph node cancers like leukemia and lymphoma. Researchers are observing and collecting health information from families with a history of these cancers to identify genetic and environmenta…